Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark R Litzow

Showing results (341-350 of 457) with videos related to

Pageof 46
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2016
A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic LeukemiaKeith W Pratz, Michelle A Rudek, Ivana Gojo, et al.
Blood|January 14, 2017
Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA eraSimon Mantha, Debra A Goldman, Sean M Devlin, et al.
Haematologica|July 28, 2011
Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemiaScott H Kaufmann, Judith E Karp, Mark R Litzow, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 15, 2012
HLA DR15 antigen status does not impact graft-versus-host disease or survival in HLA-matched sibling transplantation for hematologic malignanciesMinoo Battiwalla, Kristin Ellis, Peigang Li, et al.
Blood Cancer Journal|January 26, 2022
Molecular markers demonstrate diagnostic and prognostic value in the evaluation of myelodysplastic syndromes in cytopenia patientsRong He, Jonathan Chiou, Allison Chiou, et al.
Haematologica|June 20, 2024
FLT3 inhibitors potentially improve response rates in acute myeloid leukemia harboring t(6;9)(<i>DEK::NUP214</i>): the Mayo Clinic experienceClifford M Csizmar, Antoine N Saliba, Patricia T Greipp, et al.
JAMA|March 7, 2023
DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell TransplantLaura W Dillon, Gege Gui, Kristin M Page, et al.
Bone Marrow Transplantation|October 18, 2024
Measurable residual FLT3 tyrosine kinase domain mutations before allogeneic transplant for acute myeloid leukemiaPranay S Hegde, Georgia Andrew, Gege Gui, et al.
Biorxiv : the Preprint Server for Biology|February 24, 2023
Epigenomic mapping in B-cell acute lymphoblastic leukemia identifies transcriptional regulators and noncoding variants promoting distinct chromatin architecturesKelly R Barnett, Robert J Mobley, Jonathan D Diedrich, et al.
JAMA Oncology|February 27, 2025
Academic Community Partnership in Acute Promyelocytic Leukemia and Early Mortality: The ECOG-ACRIN EA9131 TrialAnand P Jillella, Sandra J Lee, Jessica K Altman, et al.
Pageof 46

Showing results (341-350 of 457) with videos related to

Sort By:
Pageof 46
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2016
A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic LeukemiaKeith W Pratz, Michelle A Rudek, Ivana Gojo, et al.
Blood|January 14, 2017
Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA eraSimon Mantha, Debra A Goldman, Sean M Devlin, et al.
Haematologica|July 28, 2011
Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemiaScott H Kaufmann, Judith E Karp, Mark R Litzow, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 15, 2012
HLA DR15 antigen status does not impact graft-versus-host disease or survival in HLA-matched sibling transplantation for hematologic malignanciesMinoo Battiwalla, Kristin Ellis, Peigang Li, et al.
Blood Cancer Journal|January 26, 2022
Molecular markers demonstrate diagnostic and prognostic value in the evaluation of myelodysplastic syndromes in cytopenia patientsRong He, Jonathan Chiou, Allison Chiou, et al.
Haematologica|June 20, 2024
FLT3 inhibitors potentially improve response rates in acute myeloid leukemia harboring t(6;9)(<i>DEK::NUP214</i>): the Mayo Clinic experienceClifford M Csizmar, Antoine N Saliba, Patricia T Greipp, et al.
JAMA|March 7, 2023
DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell TransplantLaura W Dillon, Gege Gui, Kristin M Page, et al.
Bone Marrow Transplantation|October 18, 2024
Measurable residual FLT3 tyrosine kinase domain mutations before allogeneic transplant for acute myeloid leukemiaPranay S Hegde, Georgia Andrew, Gege Gui, et al.
Biorxiv : the Preprint Server for Biology|February 24, 2023
Epigenomic mapping in B-cell acute lymphoblastic leukemia identifies transcriptional regulators and noncoding variants promoting distinct chromatin architecturesKelly R Barnett, Robert J Mobley, Jonathan D Diedrich, et al.
JAMA Oncology|February 27, 2025
Academic Community Partnership in Acute Promyelocytic Leukemia and Early Mortality: The ECOG-ACRIN EA9131 TrialAnand P Jillella, Sandra J Lee, Jessica K Altman, et al.
Pageof 46